Abstract:Diuretics are used widely to raise renal salt and water clearance in a variety of conditions, such as oedema, as well in non-edematous states such as hypertension, which can reduce morbidity and mortality of cardiovascular and cerebrovascular diseases, especially the frequency of stroke and congestive heart failure. However, long-term use of conventional diuretics has several adverse effects including electrolyte disorders, hyperuricemia, hyperlipidemia, and glucose tolerance decrease. Electrolyte abnormalities can induce cardiac arrythmias and sudden death. Therefore, discovering a new diuretic that does not cause electrolyte disturbance becomes a hot issue. Phenotype analysis of knockout mice lacking urea transporter UT-B or various UT-A isoforms has provided evidence for the involvement of UTs in the urinary concentrating mechanism. Functional deletion of UT-B or UT-A isoforms markedly caused polyuria and urea selective low urine concentrating ability. However, deletion of UT-B or UT-As did not affect GFR and clearance rate of the principal solutes (Na+, K+, Cl-) in urine except for urea. Therefore, we suggested a hypothesis that UT inhibitors might be novel diuretics to excrete water without disturbing electrolyte metabolism. Present study discovered a potent small-molecular urea transporter inhibitor, UT-A4, using an erythrocyte osmotic lysis assay. Stopped flow light scattering experiment, a classical assay for measuring water and urea permeability, confirmed that UT-A4 reversibly inhibited UT-B activity. The experiments also showed that UT-A4 targeted the intracellular part of UT-B protein and had the same inhibition activity on influx and efflux of urea across membrane. UTinh-14 has inhibition activity on human, rabbit, rat and mouse UT-B. We used rats as an in vivo test model for determining the diuretic activity of UT-A4. Interestingly, UT-A4 caused dose-dependent polyuria, low urinary osmolality and urea concentration in rats. 18-h water deprivation raised urine concentrating ability in rats with or without UT-A4 treatment. However, urine osmolality and urea concentration remained significantly less in UT-A4 treated rats than that in control rats, except of unchanged non-urea solutes. Osmolality and urea concentration was significantly decreased in inner medullary tissue of UTinh-14 treated rats, but not in HCTZ treated rats. All these results suggest that UTinh-14 caused urea selective diuresis. The excretion of osmoles, urea and non-urea solutes had no significant difference between control and UTinh-14 treated rats. However, HCTZ treated rats had significant higher excretion of osmole and non-urea solutes than control and UTinh-14 treated rats, which made lower blood Na+, K+ and Cl-. These results indicate that UT-A4 is a selective UT inhibitor and has urea selective diuretic activity without disturbing excretion of electrolytes. It might have potential value on drug discovery as a new diuretic without electrolyte imbalance and metabolic disorder. It might also be used as a tool drug to study the physiological roles of UTs in big animal models.

Structural characterization of human urea transporters UT-A and UT-B and their inhibition

Structural Insights into the Mechanisms of Urea Permeation and Distinct Inhibition Modes of Urea Transporters

Developing Hypothetical Inhibition Mechanism of Novel Urea Transporter B Inhibitor

Phenylphthalazines As Small-Molecule Inhibitors of Urea Transporter Ut-B and Their Binding Model

Small-molecule inhibitors of urea transporters.

Triazolothienopyrimidine inhibitors of urea transporter UT-B reduce urine concentration.

Urea Transporters Identified As Novel Diuretic Drug Targets

Structure and Permeation Mechanism of a Mammalian Urea Transporter.

Molecular basis of inhibition of the amino acid transporter B AT1 (SLC6A19)

[Renal Physiology of Urea Transporters].

Structural Insights into the Atomistic Mechanisms of Uric Acid Recognition and Translocation of Human Urate Anion Transporter 1

Discovery and Optimization of Thienopyridine Derivatives As Novel Urea Transporter Inhibitors.

Transport mechanism and structural pharmacology of human urate transporter URAT1

Structural basis for the transport and substrate selection of human urate transporter 1

Molecular basis of inhibition of the amino acid transporter B0AT1 (SLC6A19)

Discovery and Pharmacological Study of a Novel Diuretic

Structure and inhibition mechanisms of essential transporter efflux protein A

Overview and Historical Perspective.

Functional Inhibition of Urea Transporter UT-B Enhances Endothelial-Dependent Vasodilatation and Lowers Blood Pressure Via L-arginine-endothelial Nitric Oxide Synthase-Nitric Oxide Pathway

Substrate Recognition Properties from an Intermediate Structural State of the UreA Transporter

Discovery of Thienoquinolin Urea Transporter Inhibitors Acts As a Potential Diuretic (LB587)